Metagenomi Therapeutics (MGX) Cash from Investing Activities (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Cash from Investing Activities data on file, last reported at $4.0 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $4.0 million, down 83.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.8 million (up 164.47% YoY), and the FY2025 annual result was $103.5 million, up 217.44% from the prior year.
• Cash from Investing Activities fell to $4.0 million in Q1 2026 per MGX's latest filing, from $32.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $75.9 million in Q3 2023 and troughed at -$94.7 million in Q1 2024.
• A 4-year average of $5.0 million and a median of $19.1 million in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities slumped 111.77% in 2024, then soared 406.28% in 2025.
• A 4-year view of Cash from Investing Activities shows it stood at $60.6 million in 2023, then slumped by 52.92% to $28.5 million in 2024, then advanced by 13.39% to $32.4 million in 2025, then plunged by 87.68% to $4.0 million in 2026.
• Business Quant data shows MGX's Cash from Investing Activities at $4.0 million in Q1 2026, $32.4 million in Q4 2025, and $27.4 million in Q3 2025.